InterVenn
InterVenn, founded in 2017, developed the GlycoVision™ platform to enhance glycoproteomics for biomarker discovery, disease detection, and therapeutic monitoring. Their AI-driven technology integrates liquid chromatography-tandem mass spectrometry (LC-MS/MS) to provide detailed glycoproteomic analysis.
Company Overview
InterVenn was founded in 2017 and specializes in glycoproteomics, which involves the systems-wide study of glycoproteins. Glycoproteins play critical roles in biological processes. The company has developed advanced platforms for glycoproteomic analysis that integrate liquid chromatography-tandem mass spectrometry (LC-MS/MS) with AI-based software. These innovations enable new insights into biomarker discovery, disease detection and progression, therapeutic response, and monitoring.
Products
InterVenn's product lineup includes GlycoVision™ and GlycoKnow™ Colon. GlycoVision™ is the first commercially available glycoproteomic platform that provides early disease detection, response prediction, disease prognosis, and therapeutic monitoring. It detects approximately 700 of the most highly abundant glycoisoforms found in blood. GlycoKnow™ Colon is a blood-based laboratory-developed test designed for the early detection of colorectal cancer, specifically assessing the presence of adenomas with high-grade dysplasia or colorectal cancer.
Technological Innovations
InterVenn utilizes an AI-driven platform that leverages liquid chromatography-tandem mass spectrometry (LC-MS/MS) for glycoproteomic analysis. The AI platform can annotate chromatograms with over 99% concordance to expert analyses and translates LC-MS data into quantitative biomarker data. InterVenn's technology does not rely on tumor-produced biomarkers but instead focuses on the host immune system for early disease detection. Their glycoproteomic studies have identified specific glycan structures associated with various diseases, including cancer, infectious, neurodegenerative, and inflammatory diseases.
GlycoVision™ Platform
InterVenn's GlycoVision™ platform significantly improves the speed, scope, and scale of glycoproteomic analysis. This platform provides unparalleled detail in unlocking the glycoproteome and is the first of its kind available commercially for disease detection and therapeutic monitoring. It detects approximately 700 of the most highly abundant glycoisoforms in blood and integrates advanced liquid chromatography with AI-driven software. The platform is part of InterVenn’s efforts to offer new insights into biomarker discovery, disease progression, and therapeutic response.
Clinical and Regulatory Compliance
InterVenn's clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). This certification ensures that the laboratory meets stringent quality and operational standards, which is crucial for the accuracy and reliability of their glycoproteomic analyses. The company's dedication to compliance is integral to their mission of advancing early disease detection and therapeutic monitoring through innovative technology.